Publications | Lund University Publications

1 – 9 of 9

show: 10
|
sort: year (new to old)

News feed Embed this list Save this search Mark all Export

Cancel

Embed this list

copy and paste the html snippet below into your own page:

<iframe src="https://lup.lub.lu.se/search/publication?embed=1&q=keywords+exact+%22Vildagliptin%22&amp;hide_pagination=1&amp;hide_info=1&amp;hide_options=1"
  width="100%"
  height="400"
  allowtransparency="true"
  frameborder="0">
</iframe>

2020
Mark Persistent whole day meal effects of three dipeptidyl peptidase-4 inhibitors on glycaemia and hormonal responses in metformin-treated type 2 diabetes
Alsalim, Wathik ^LU ; Göransson, Olga ^LU ; Tura, Andrea ; Pacini, Giovanni ; Mari, Andrea and Ahrén, Bo ^LU (2020) In Diabetes, Obesity and Metabolism 22(4). p.590-598
- Contribution to journal › Article
2018
Mark Different glucagon effects during DPP-4 inhibition versus SGLT-2 inhibition in metformin-treated type 2 diabetes patients
Alsalim, Wathik ^LU ; Persson, Margaretha ^LU and Ahrén, Bo ^LU (2018) In Diabetes, Obesity and Metabolism 20(7). p.1652-1658
- Contribution to journal › Article
2017
Mark The vildagliptin experience - 25 years since the initiation of the novartis glucagon-like peptide-1 based therapy programme and 10 years since the first vildagliptin registration
Foley, James E and Ahrén, Bo ^LU (2017) In European Endocrinology 13(2). p.56-61
- Contribution to journal › Article
2011
Mark GLP-1 for type 2 diabetes
Ahrén, Bo ^LU (2011) In Experimental Cell Research 317(9). p.1239-1245
- Contribution to journal › Scientific review
2010
Mark Vildagliptin add-on to metformin produces similar efficacy and reduced hypoglycaemic risk compared with glimepiride, with no weight gain: results from a 2-year study
Matthews, D. R. ; Dejager, S. ; Ahrén, Bo ^LU ; Fonseca, V. ; Ferrannini, E. ; Couturier, A. ; Foley, J. E. and Zinman, B. (2010) In Diabetes, Obesity and Metabolism 12(9). p.780-789
- Contribution to journal › Article
2009
Mark Fifty-two-week efficacy and safety of vildagliptin vs. glimepiride in patients with type 2 diabetes mellitus inadequately controlled on metformin monotherapy
Ferrannini, E. ; Fonseca, V. ; Zinman, B. ; Matthews, D. ; Ahrén, Bo ^LU ; Byiers, S. ; Shao, Q. and Dejager, S. (2009) In Diabetes, Obesity and Metabolism 11(2). p.157-166
- Contribution to journal › Article
2008
Mark Evidence that vildagliptin attenuates deterioration of glycaemic control during 2-year treatment of patients with type 2 diabetes and mild hyperglycaemia
Scherbaum, W. A. ; Schweizer, A. ; Mari, A. ; Nilsson, Peter ^LU ; Lalanne, G. ; Wang, Y. ; Dunning, B. E. and Foley, J. E. (2008) In Diabetes, Obesity and Metabolism 10(11). p.1114-1124
- Contribution to journal › Article
2007
Mark DPP-4 inhibition improves glucose tolerance and increases insulin and GLP-1 responses to gastric glucose in association with normalized islet topography in mice with beta-cell-specific overexpression of human islet amyloid polypeptide.
Ahrén, Bo ^LU ; Winzell, Maria Sorhede ; Wierup, Nils ^LU ; Sundler, Frank ^LU ; Burkey, Bryan and Hughes, Thomas E (2007) In Regulatory Peptides 143(1-3). p.97-103
- Contribution to journal › Article
2006
Mark Vildagliptin: an inhibitor of dipeptidyl peptidase-4 with antidiabetic properties.
Ahrén, Bo ^LU (2006) In Expert Opinion on Investigational Drugs 15(4). p.431-442
- Contribution to journal › Article

your query:: Remove keywords: Vildagliptin